Market access is multidisciplinary and deadline-driven. A single reimbursement outcome may depend on payer-relevant evidence strategy, economic modeling, country process navigation, contracting design, and operational readiness for coding, claims, site-of-care economics, and patient initiation. Few organizations have deep strength in every element at every moment. External partners can close gaps, accelerate decisions, and reduce risk, but only when they are used deliberately and anchored to specific payer decisions and implementation mechanics.
18.1 When to Bring in External Support on Market Access
External support is justified when the access outcome is high-stakes, time-bound, novel to the organization, or constrained by a capability or capacity gap. The question is not whether the team is talented. The question is whether the organization can deliver the right work at the right standard before the payer decision window closes.
Bring external support when: one or more of these conditions is true.
- Critical decision windows: HTA submission, national price negotiation, tender, or U.S. formulary cycle where a miss would delay access or force unfavorable concessions.
- Capability gaps: missing expertise in indirect comparisons, cost-effectiveness and budget impact standards, outcomes contracting, coding and reimbursement operations, or tender strategy.
- Scale and parallelism: multiple priority markets running in parallel, where speed and consistency matter more than bespoke work.
- High uncertainty: rare disease, cell and gene, or first-in-class assets where evidence gaps must be managed with feasible safeguards and commitments.
- Access rescue: underperformance driven by restrictions, denial spikes, site-of-care economics, or policy drift that requires rapid diagnosis and fixes.
- Independent validation: leadership needs a credible second view before changing corridor guardrails or accepting novel access models.
External support is usually a poor investment when the bottleneck is internal decision latency. If the organization cannot decide on population boundaries, concession triggers, or ownership of operational readiness, an external team will not fix the core problem. Establish decision rights and a gate-based cadence first, then add external horsepower to accelerate execution.
A practical build-versus-buy test is to assess three dimensions. Time: can the internal team learn and deliver before the decision window? Quality: can the internal team deliver at a standard that will withstand technical assessor scrutiny and payer operations reality? Opportunity cost: what high-value work will be delayed if the team tries to do everything itself? If any dimension is unfavorable, external support is usually justified.
It is also useful to separate knowledge work: decisions and judgment that set risk-bearing choices, from production work: outputs that can be built once those choices are locked. Most companies should keep knowledge work internal: access ambition, population boundaries, non-negotiable claims, corridor guardrails, and any commitments that create ongoing obligations. External partners are often best used for production work: building models, drafting dossier modules, preparing country packs, and running structured payer research. Mixing these categories is a common source of frustration, because partners cannot “produce” their way out of unresolved internal trade-offs.
Once ownership is clear, choose the lightest external configuration that solves the problem. A single decision and a single deliverable often fit a sprint or an embedded expert. Multiple markets and multiple deliverables often require a managed cadence, and sometimes a combination of partner types.
Common support patterns:
- Strategy plus production: a strategy team defines ambition and trade-offs, while a specialist agency builds technical deliverables.
- Player-coach model: an independent senior expert guides decisions and reviews outputs, while internal teams execute.
- Hybrid launch model: a large firm runs the cross-functional program and governance, with local experts for priority markets.
- Operational rescue model: an operational expert diagnoses denials and site-of-care issues, paired with internal operations teams to implement fixes.
Choose external help by role. Market access support typically fits four roles: Strategy architect: defines options and trade-offs. Technical builder: produces auditable models and dossiers. Country accelerator: navigates local process and stakeholder dynamics. Operational fixer: removes friction in coding, billing, denials, and site-of-care economics. Hiring for one role and expecting another is a common failure mode.
Checklist: clarify these items before you staff external support.
- Decision owner: who approves access ambition, corridor, give-gets, and post-launch commitments.
- Non-negotiables: which claims, populations, and assumptions cannot change without escalation.
- Inputs: what evidence, costs, epidemiology, and pathway information will be provided and when.
- Interfaces: how the partner will work with HEOR, medical, commercial, legal, and finance.
- Success measures: the two or three outcomes that define success beyond “deliverables delivered.”
18.2 Large Consulting Firms: Offerings, Strengths, and Limitations
Large multidisciplinary consulting firms are most useful when you need integrated problem solving across strategy, analytics, operating model, and change management—particularly when cross-functional alignment is the bottleneck. Their core value is orchestration: they can structure complex work, mobilize quickly, and drive decisions across functions and geographies.
Typical offerings:
- Access strategy and launch sequencing: market clustering, launch order, and global-to-local cascade design.
- Pricing architecture and governance: corridor setting, reference-pricing risk management, and concession approval rules.
- Operating model: decision rights, forums, cadence, and access performance dashboards.
- Access rescue: diagnostics and implementation plans for restrictions and operational friction.
Strengths:
- Executive alignment: structured facilitation that converts debate into decisions.
- Program management: disciplined workplans, sequencing, and accountability across workstreams.
- Cross-functional integration: connecting evidence, pricing, contracting, and operations into coherent choices.
- Change enablement: embedding processes so the organization can repeat success across launches.
Limitations:
- Local depth: deep, current country execution detail may require local specialists.
- Technical production: HTA-grade modeling often requires HEOR specialists and dedicated QC pipelines.
- Cost: large-team leverage can be expensive if scope and decision cadence are not tight.
- Dependency: if internal teams do not co-own artifacts and decisions, capability does not transfer.
Large firms are a strong fit when the problem is as much organizational as technical. Examples include aligning leadership on the global access ambition and the minimum viable evidence plan, reconciling commercial and finance on net scenarios, standing up a launch-to-performance control tower, or redesigning the access operating model after repeated launch friction. They are less efficient when the need is a narrow technical artifact or a single-market tactic.
To control cost, separate integration leadership: technical production:
Large firms deliver best results when the engagement is designed around decision gates. Ask for a small set of decision artifacts leaders will use: an access ambition by segment, a corridor and give-get menu, a negotiation posture with escalation rules, and an implementation readiness plan. Avoid vague “full strategy” scopes that invite endless iteration without closure.
Be explicit about staffing. Large firms often blend senior leadership with junior delivery teams. That model works when tasks are repeatable and quality-controlled. It fails when the work requires continuous senior judgment. Define which decisions require senior partner involvement and insist that the named senior lead attends those forums.
Checklist: how to scope large-firm work to maximize value.
- Decision gates: define the few decision moments the engagement must support.
- Artifacts: specify the outputs leaders will read and approve.
- Senior involvement: define which forums require senior partner time.
- Local expertise plan: specify how country specialists will be incorporated where needed.
- Handover: define how internal teams will own and maintain outputs after the engagement.
18.3 Specialist Market Access Agencies and HEOR Consultancies
Specialist market access agencies and HEOR consultancies are strongest in technical depth and payer-facing production. They bring methodologists, established QC, and familiarity with local submission standards. They are most valuable when the deliverable must withstand technical scrutiny and when internal teams cannot produce to that standard fast enough.
Best-fit use cases:
- Economic models: cost-effectiveness and budget impact models built to local method expectations with full documentation.
- Evidence synthesis: systematic literature review and indirect comparisons with transparent assumptions.
- Dossier production: global dossier modules and local adaptations with consistency controls.
- Payer research: structured insights and objection mapping within compliant boundaries.
- RWE planning: feasible post-launch evidence plans tied to payer uncertainty and reassessment.
To use specialists well, provide a short decision brief that defines the target reimbursed population, the comparator reality, the endpoints that matter, and the objections you expect. Require that every major deliverable includes a plain-language driver summary so leadership can see what moves results and where uncertainty remains.
Quality control must be explicit: technical failures are often basic and preventable. Require version control with a change log and run a structured QC checklist before any payer-facing use.
- Coherence: population, comparator, endpoints, and horizon match across modules.
- Traceability: inputs are sourced and auditable; calculations are replicable.
- Robustness: sensitivities reflect plausible ranges and highlight fragility points.
- Implementation realism: scenarios reflect likely restrictions, phasing, and pathway constraints.
Specialist teams can overbuild analyses that do not change decisions, and they can produce excellent technical work that is not translated into negotiation posture or implementable criteria. Prevent this by running scheduled integration reviews where access, pricing, medical, and HEOR translate outputs into three things: the criteria language you want payers to adopt, the give-get choices you are willing to use, and the operational feasibility checks that ensure the policy can be implemented without denial spikes.
Also plan for the review cycle, not just submission. Technical assessors commonly ask for clarifications and alternative scenarios under time pressure. Build a controlled “technical response pack” so you can respond quickly without creating inconsistent versions of the story.
Template: technical response pack contents.
- Likely questions:
- Response logic:
- Supporting outputs:
- Change rules:
Finally, align assumptions to your access ambition. If you expect initial reimbursement in a subset, the base case should reflect that subset. If access is likely to be phased, budget impact should reflect phasing. If diagnostics or site capacity constrain use, scenarios should include those constraints. Analyses that mirror real policy conditions are harder to dismiss and often reduce the payer’s need to impose blunt restrictions.
18.4 Independent Market Access Consultants and Networks
Independent consultants can provide senior judgment and narrow expertise quickly, without the overhead of a large team. Many are former market access leaders, payer executives, HEOR experts, or country specialists. They are especially valuable when you need a player-coach to sharpen strategy, de-risk negotiations, or fix a specific bottleneck.
Independents add value by shortening the distance between problem and decision. They pressure-test population boundaries, comparator choices, and concession logic; translate payer feedback into actionable changes; and bring practical knowledge of how criteria are operationalized in real payer systems. They are also effective as hostile reviewers who can detect coherence gaps before assessors do.
Independent consultants via Umbrex:
Independents can also fill fractional leadership gaps. Some companies use an independent as an interim global access lead for an asset, a temporary head of U.S. payer strategy during launch, or a short-term country lead to run a submission and negotiation cycle. This works when decision rights are explicit and the independent operates within guardrails, not by inventing new rules.
Independents work best when the scope is defined as a set of expert decisions and usable artifacts, not as open-ended advisory. Typical outputs include: a strategy memo with options and trade-offs; a negotiation posture and give-get menu; a denial-driver diagnostic with prioritized fixes; or a dossier coherence review with a list of required corrections. Assign an internal owner, integrate the consultant into the weekly cadence, and require documentation so capability remains in-house.
Checklist:
- Relevant reps:
- Market specificity:
- Working artifacts:
- Availability:
- Integration:
Strengths:
- Precision:
- Speed:
- Flexibility:
- Cost efficiency:
Limitations:
- Capacity:
- Execution reliance:
- Production constraints:
A common high-performing pattern is hybrid: an independent senior expert as strategy and quality lead, specialist agencies for technical production, and internal teams as owners and implementers. This combination maintains coherence while keeping cost and complexity under control.
18.5 Designing and Managing Effective External Engagements
External engagements succeed when scope is clear, outputs are decision-linked, and governance is tight. They fail when deliverables are vague, decision rights are unclear, and iteration is unmanaged. Design the engagement so it produces decisions and executable artifacts, not just analysis.
Design principles: keep the engagement anchored to payer decisions, enforce a single source of truth for population and comparator definitions, and build knowledge transfer into the work rather than at the end.
Template:
- Objective:
- Scope:
- Assumptions:
- Inputs:
- Governance:
- Deliverables:
Template:
- Progress:
- Decisions needed:
- Risks:
- Next steps:
Pay attention to data and IP handling. Define what data the partner can access, how it will be stored, and how outputs will be retained after the engagement. For models and dossiers, require editable working files and documentation sufficient to update them later. If subcontractors are involved, require transparency on who is doing the work and apply the same confidentiality and review rules.
Checklist:
- Internal owner:
- Decision cadence:
- Single source of truth:
- Outcome KPIs:
- Knowledge transfer:
- Compliance controls:
Template:
- Final artifacts:
- Assumptions log:
- Methods note:
- Objection library:
- Lessons learned:
Close engagements with a handover that enables reuse. If the organization cannot defend the work after the partner leaves, the engagement did not deliver durable value.
